Search Results

Renal Research Institute, a global leader in dialysis and nephrology research and a subsidiary of Fresenius Medical Care AG, announced together with the Karolinska Institutet a joint symposium, “Prevention of CKD progression: the impact of new therapeutics.” The Karolinska Institutet is one of the world’s leading medical universities.

Coya Therapeutics, Inc. announces the expansion of its research collaboration with the Houston Methodist Research Institute (“HMRI”) through a sponsored research agreement (SRA) covering multiple initiatives.

Providence Therapeutic Holdings Inc. and the Ontario Institute for Cancer Research, Ontario’s largest publicly funded cancer research institute delivering real-world solutions to people affected by cancer, announced the signing of a collaboration agreement for mRNA drug discovery and development.

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator.

Kyverna Therapeutics, Inc. announced the publication in Nature Reviews Immunology of a manuscript co-authored with the National Institutes of Health titled “Chimeric antigen receptor T cell therapy for autoimmune disease”.

Senti Biosciences, Inc., a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, announced that the California Institute for Regenerative Medicines has awarded an $8 million grant to Senti Bio.

Oblique Therapeutics, a leading biotechnology company specialising in the development of new drug candidates, is pleased to announce today that they have entered into an agreement with the KTH Royal Institute of Technology to utilise KTH’s state-of-the-art supercomputer resources for analysing protein structures.

Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC.